Management of colorectal cancer in the era of COVID-19: Challenges and suggestions

W Alam, Y Bouferraa, Y Haibe, D Mukherji… - Science …, 2021 - journals.sagepub.com
The Coronavirus (COVID-19) pandemic had a huge impact on all sectors around the world.
In particular, the healthcare system has been subject to an enormous pressure that has …

Guidance for Treating the Older Adults with Colorectal Cancer

D Ioffe, E Dotan - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement The need for evidence-based data in the rapidly growing group of older
patients is vast and more elderly-specific studies are desperately needed, for which there is …

[HTML][HTML] Treatments after second progression in metastatic colorectal cancer: a pooled analysis of the TRIBE and TRIBE2 studies

D Rossini, MM Germani, S Lonardi… - European Journal of …, 2022 - Elsevier
Background The availability of new drugs in the chemo-refractory setting opened the way to
the concepts of treatment sequencing in mCRC. However, the impact of later line options in …

Update on the management of elderly patients with colorectal cancer

G Soler-González, J Sastre-Valera… - Clinical and …, 2024 - Springer
Colorectal cancer (CRC) is one of the most common tumours worldwide, and 70% of CRC
patients are over 65 years of age. However, the scientific evidence available for these …

Assessing oncologists' adoption of biomarker testing in metastatic colorectal cancer using real-world data

P Iyer, M Deng, EA Handorf, S Nakhoda… - JNCI Cancer …, 2022 - academic.oup.com
Background Despite national guideline recommendations for universal biomarker testing
(KRAS, NRAS, BRAF, and mismatch repair and microsatellite instability [MMR/MSI]) in all …

[HTML][HTML] Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre …

A Raimondi, G Fucà, AG Leone, S Lonardi, C Antoniotti… - ESMO open, 2021 - Elsevier
Background The safety and efficacy outcome of elderly metastatic colorectal cancer (mCRC)
patients fit enough to receive combination chemotherapy plus biological agents is an issue …

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil …

G Sommerhäuser, A Kurreck, S Stintzing, V Heinemann… - BMC cancer, 2022 - Springer
Background Initial systemic therapy for patients with metastatic colorectal cancer (mCRC) is
usually based on two-or three-drug chemotherapy regimens with fluoropyrimidine (5 …

Efficacy and safety of systemic treatments among colorectal cancer patients: A network meta-analysis of randomized controlled trials

T Hoang, DK Sohn, BC Kim, Y Cha, J Kim - Frontiers in Oncology, 2022 - frontiersin.org
Background Systemic treatments, namely, either monotherapy or combination therapy, are
commonly administered to patients with advanced or metastatic colorectal cancer (CRC) …

Integration of geriatric assessment into routine oncologic care and advances in geriatric oncology: A young International Society of Geriatric Oncology Report of the …

S Giri, C Chakiba, YY Shih, WL Chan… - Journal of geriatric …, 2020 - Elsevier
Rising to the pandemic challenge, the American Society of Clinical Oncology (ASCO)
convened the 2020 Annual Meeting in a virtual format as oncology stakeholders reviewed …

Chemotherapy and targeted agents in the treatment of elderly patients with metastatic colorectal cancer

A Tuca, R Gallego, I Ghanem, M Gil-Raga… - Journal of Clinical …, 2020 - mdpi.com
Colorectal cancer (CRC) is one of the main causes of cancer death in the elderly. The older
patients constitute a heterogeneous group in terms of functional status, comorbidities, and …